Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study in Children and Adolescents With Birch Pollen-induced Rhinoconjunctivitis (TreeTop)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04878354
Recruitment Status : Recruiting
First Posted : May 7, 2021
Last Update Posted : June 30, 2022
Sponsor:
Collaborator:
Parexel
Information provided by (Responsible Party):
ALK-Abelló A/S

Brief Summary:

This is a clinical study in children and adolescents (5-17 years) with allergy to pollen from birch (or related trees). It compares the tree SLIT-tablet with placebo in relieving rhinoconjunctivitis symptoms during the birch/tree pollen season based on the average allergic rhinoconjunctivitis daily total combined score.

The study will also collect health-related quality of life information in the groups treated with the tree SLIT-tablet or with placebo during the pollen season.

The trial medication used is already approved to treat allergic rhinitis caused by birch/tree pollen in adults in several countries?.


Condition or disease Intervention/treatment Phase
Allergy Drug: SQ tree SLIT-tablet Drug: Placebo Phase 3

Detailed Description:

This is a phase III, parallel-group, double-blind, placebo-controlled study to evaluate efficacy and safety of the tree SLIT-tablet in children and adolescents (5-17 years) who have rhinoconjunctivitis (with or without asthma) induced by pollen from birch trees or by trees belonging to the birch homologous group. Approximately 1000 children and adolescents will be enrolled in the trial and will receive either the tree SLIT-tablet or placebo.

The trial consists of 3 periods: a screening period, a treatment period, which includes pre-seasonal and co seasonal treatment, and a follow-up period. The duration is up to 13 months for each participant.

The trial is conducted in several European countries and in Canada.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of the SQ Tree Sublingual Immunotherapy Tablet in Children and Adolescents With Moderate to Severe Allergic Rhinitis and/or Conjunctivitis Induced by Pollen From Birch and Trees Belonging to the Birch Homologous Group
Actual Study Start Date : April 7, 2021
Estimated Primary Completion Date : July 17, 2023
Estimated Study Completion Date : September 30, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy

Arm Intervention/treatment
Placebo Comparator: Placebo
Gelatine (fish source), mannitol and sodium hydroxide
Drug: Placebo
Placebo

Experimental: Intervention/treatment
Sublingual allergy immunotherapy tablet, for daily administration SQ tree SLIT-tablet
Drug: SQ tree SLIT-tablet
Sublingual allergy immunotherapy tablets




Primary Outcome Measures :
  1. Average total combined score (rhinoconjunctivitis symptoms and medication use) during the birch pollen season [ Time Frame: 3 months ]
    European Academy of Allergy and Clinical Immunology - values 0,1,2 (The higher score means more symptoms and more rescue medication used)


Secondary Outcome Measures :
  1. Average total combined score (rhinoconjunctivitis symptoms and medication use) during the tree pollen season [ Time Frame: 6 months ]
    European Academy of Allergy and Clinical Immunology - values 0,1,2 (The higher score means more symptoms and more rescue medication used)

  2. Average daily symptom score during the birch pollen season [ Time Frame: 3 months ]
    Sum of the 6 allergic rhinoconjunctivitis symptom scores; No symptoms (0), Mild symptoms (1), Moderate symptoms (2), Severe symptoms (3). Total scores will be between 0-18 (higher scores means more symptoms)

  3. Average daily symptom score during the tree pollen season [ Time Frame: 6 months ]
    Sum of the 6 allergic rhinoconjunctivitis symptom scores; No symptoms (0), Mild symptoms (1), Moderate symptoms (2), Severe symptoms (3). Total scores will be between 0-18 (higher scores means more symptoms)

  4. Average daily medication score during the birch pollen season [ Time Frame: 3 months ]
    The type and dose of rescue medication will be scored. Scores between 0-20 (the higher value means the most rescue medication used)

  5. Average daily medication score during the tree pollen season [ Time Frame: 6 months ]
    The type and dose of rescue medication will be scored. Scores between 0-20 (the higher value means the most rescue medication used)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   5 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female of any race/ethnicity aged ≥4 to <18 years on the day informed consent is obtained from the parent/caregiver; the subject must be ≥5 to <18 years old at the randomisation visit
  • A documented , physician diagnosed, clinically relevant history of moderate to severe AR/C induced by birch pollen (with or without asthma) despite having received treatment with symptom-relieving medication during at least 1 previous tree pollen season for ages 4 through 6 years at screening or at least 2 previous tree pollen seasons for ages 7 through 17 years at screening
  • Positive skin prick test (SPT) to Betula verrucosa at screening
  • Positive specific IgE to Bet v at screening
  • Presence of 1 or more of the following Allergic Rhinitis Impact on Asthma (ARIA) quality of life items due to AR/C during the previous BPS:

    1. Sleep disturbance
    2. Impairment of daily activities, leisure and/or sport
    3. Impairment of school or work
    4. Troublesome symptoms

Exclusion Criteria:

  • A clinically relevant history of symptomatic seasonal AR/C caused by an allergen source, other than tree pollen from the birch homologous group, with a season overlapping the TPS
  • A clinically relevant history of symptomatic perennial AR/C caused by an allergen source such as animal hair and dander to which the subject is exposed during the TPS
  • Any clinical deterioration of asthma (i.e. asthma exacerbation) that resulted in emergency treatment, hospitalisation or treatment with systemic corticosteroids within 3 months prior to randomisation
  • Reduced lung function at randomisation defined as forced expiratory volume in 1 second (FEV1) <70% of predicted value. For subjects with asthma, this is assessed on subject's usual asthma medication following at least a 6-hour wash-out of SABA. This criterion does not need to be fulfilled if the subject is <7 years old, cannot perform reproducible FEV1 manoeuvres despite coaching and is not considered as having a diagnosis of asthma
  • Ongoing treatment with any allergy immunotherapy product
  • Severe chronic oral inflammation
  • A diagnosis of eosinophilic oesophagitis
  • A relevant history of systemic allergic reaction e.g. anaphylaxis with cardiorespiratory symptoms, generalised urticaria or severe facial angioedema that in the opinion of the investigator may constitute an increased safety concern
  • Immunosuppressive treatment (ATC code L04 or L01) within 3 months prior to the screening visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04878354


Contacts
Layout table for location contacts
Contact: Clinical Project Manager +4545747576 clinicaltrials@alk.net

Locations
Show Show 68 study locations
Sponsors and Collaborators
ALK-Abelló A/S
Parexel
Investigators
Layout table for investigator information
Principal Investigator: Monika Gappa, Prof. MD Evangelisches Krankenhaus Düsseldorf
Layout table for additonal information
Responsible Party: ALK-Abelló A/S
ClinicalTrials.gov Identifier: NCT04878354    
Other Study ID Numbers: TT-06
2020-004372-17 ( EudraCT Number )
First Posted: May 7, 2021    Key Record Dates
Last Update Posted: June 30, 2022
Last Verified: June 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ALK-Abelló A/S:
Allergic rhinoconjunctivitis
Children
Adolescents
Birch